Short-duration psychedelic therapy shows promise for major depression treatment
A controlled clinical trial suggests a fast-acting psychedelic approach may reduce depressive symptoms, but researchers stress careful interpretation…
Psychedelic effects of ketamine do not predict sobriety
The psychedelic effects recreational users often seek from taking ketamine do not predict the therapeutic benefits for people…
Big breakfast study reveals protein curbs appetite but fiber delivers stronger gut microbiome benefits
A controlled clinical trial shows that what you eat at breakfast, not just how much, may shape appetite,…
High adherence and safety found in short TB treatments
A study comparing one- and three-month antibiotic treatments to prevent active tuberculosis (TB) finds that a high percentage…
University of Missouri launches first on-campus radiopharmaceutical clinical trial
In a major leap for cancer care at the University of Missouri, the School of Medicine and MU…
Tirzepatide shows dual benefits in sleep apnea trial improving metabolism and reducing inflammation
New clinical trial evidence suggests targeting both obesity and sleep-disordered breathing together may reshape cardiometabolic risk management in…
Novel neuroprotective drug improves recovery after acute ischemic stroke
Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting within 48…
Eating beef as part of a healthy dietary pattern does not impact risk factors for type 2 diabetes
More than 135 million American adults are either living with or at risk for type 2 diabetes (T2D),…
Regular aerobic exercise slows a key marker of brain aging in midlife
A year of consistent aerobic activity didn’t just boost fitness; it shifted MRI-based brain age in early to…
AskBio Announces FDA Acceptance of Investigational New Drug (IND) Application for AB-1009 Gene Therapy for Treatment of Late-Onset Pompe Disease (LOPD)
Durham, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) — AB-1009 program advances to Phase 1/Phase 2; clinical trial initiated…
Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
In TRIUMPH-4, participants with obesity and knee osteoarthritis taking retatrutide 12 mg lost an average of 28.7% of…
UC Irvine receives funding for clinical trial of neural stem cell therapy for Huntington’s disease
Leslie M. Thompson, Donald Bren Professor of psychiatry and human behavior as well as neurobiology and behavior at…